Tislelizumab Shows Improvements in Efficacy Vs Chemo in Esophageal Cancer
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Tislelizumab Approval Adds to Armamentarium in Metastatic Esophageal Cancer
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Gastric Cancer
This comprehensive guide for oncologists covers the diagnosis, staging, treatment, and management of gastric cancer.